Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient
                    Management in Increased-Risk Thyroid Cancer

AbstractThe aim of the study was to evaluate the clinical impact of pre-ablation rhTSH-stimulated fluorine-18 fluorodeoxyglucose (F-18 FDG) PET/CT in addition to post-therapeutic whole body radioiodine scanning in patients with intermediate to high risk differentiated thyroid carcinoma (DTC). This was a retrospective single center study including 73 patients with thyroid cancer (44 females, mean age 43.2±16.2 years, 62% papillary, 31% follicular, 7% poorly differentiated). All patients underwent ablative radioiodine treatment (mean activity: 3661±673 MBq I-131) using rhTSH after thyroidectomy and lymph node (LN) dissection (01/2013–10/2016) and TSH-stimulated F-18 FDG PET/CT (4 MBq/kg body weight, low dose CT). Post-treatment I-131 whole body scan (I-131 WBS) was obtained 9 days afterwards in planar technique and in case of equivocal or abnormal findings using SPECT/CT. Thirty-one patients (42%) showed F-18 FDG avid lesions, 14 patients showed more FDG than iodine positive lesions and 5 patients more iodine positive lesions in I-131 WBS, respectively. Fifty-three patients showed identical F-18 FDG PET/CT and I-131 WBS. The initial treatment plan was changed from follow-up to therapy (surgery, systemic therapy using tyrosine-kinase inhibition) in 11 patients (15%) on the basis of F-18 FDG PET/CT imaging. Six of these 11 patients had papillary thyroid cancer. Three patients with histologically proven LN metastases had stimulated thyroglobulin-levels<2.0 ng/ml. Our study demonstrated a clinical benefit of pre-ablation rhTSH-stimulated F-18 FDG PET/CT imaging in about 20% of patients with intermediate to high risk DTC, leading to change in patient management in 15%.

Download Full-text

Initial [18F]FDG PET/CT in high-risk DTC patients

Nuklearmedizin ◽

10.3413/nukmed-0766-15-09 ◽

2016 ◽

Vol 55 (03) ◽

pp. 99-103 ◽

Cited By ~ 7

Author(s):

Ina Binse ◽

Andreas Bockisch ◽

Sandra Rosenbaum-Krumme ◽

Marcus Ruhlmann

Keyword(s):

High Risk ◽

Fdg Pet ◽

Patient Management ◽

Whole Body ◽

Prognostic Impact ◽

Full Remission ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

SummaryIn a previous paper, we published the impact of initial [18F]FDG PET/CT (FDG-PET/CT) in high-risk patients with differentiated thyroid cancer (DTC) and described the changes in therapy management. The aim of the present study was to evaluate the prognostic impact of the initial FDG-PET/CT on a patient’s follow-up over three years and the rate of complete remission. Patients, methods: This study included 109 DTC patients who underwent radioiodine treatment (RIT), including posttherapeutic whole-body scintigraphy with FDG-PET/CT and a follow-up over three years. The follow-up included high-resolution sonography of the neck and determination of serum Tg as well as Tg antibodies every six months. The results of initial FDG-PET/CT and whole-body scintigraphy were compared with the status after three years of follow-up. Results: 24/109 patients (22%) presented FDG-positive lesions, 22/109 patients (20%) only iodine-positive lesions, and 63/109 patients (58%) neither FDG-positive nor iodine-positive lesions. After three years, 83/109 patients (76%) revealed full remission, 15/109 patients (14%) tumour persistence and 11/109 patients (10%) a progressive disease. The negative predictive value (NPV) was calculated for patients without FDG-positive lesions (NPV 85%) and patients without any lesions (NPV 91%) regarding full remission in the follow-up. Conclusion: FDG-PET/CT has a high NPV (85% to 91%) in DTC patients regarding recurrence-free follow-up after three years. The change in patient management in patients with iodine-negative lesions can lead to a higher rate of full remissions in the follow-up after additional surgery. Therefore, FDG-PET/ CT should be performed in all high-risk DTC patients in the context of the first RIT to improve patient management and risk stratification.

Download Full-text

Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies

Nuclear Medicine Communications ◽

10.1097/mnm.0b013e32836066c0 ◽

2013 ◽

Vol 34 (6) ◽

pp. 540-543 ◽

Cited By ~ 8

Author(s):

Kuruva Manohar ◽

Anish Bhattacharya ◽

Bhagwant R. Mittal

Keyword(s):

Fdg Pet ◽

Ct Imaging ◽

Whole Body ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct ◽

The Brain

Download Full-text

Leydig cell tumor of the testis: an incidental finding at 18F-FDG PET/CT imaging

Egyptian Journal of Radiology and Nuclear Medicine ◽

10.1186/s43055-021-00646-3 ◽

2021 ◽

Vol 52 (1) ◽

Author(s):

Almalki Yassir

Keyword(s):

Leydig Cell ◽

Fdg Pet ◽

Chronic Rejection ◽

Ct Imaging ◽

The Body ◽

Whole Body ◽

Pet Ct ◽

18F Fdg ◽

The Right ◽

Fdg Pet Ct

Abstract Background Leydig cell tumors (LCTs) represent the most common form of stromal tumors. We reported the 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) findings of a patient with testicular LCT. Case presentation A 50-year-old man with a history of end-stage renal disease and renal transplantation 19 years ago. One year earlier, he started to have a chronic rejection. During the investigation to determine the cause of chronic rejection, a suspicious lesion in the graft with a collection around it was seen on ultrasound (US) images, raising the possibility of post-transplant lymphoproliferative disorder (PTLD). The patient was referred for further evaluation by whole body 18F-FDG PET/CT imaging. The image finding revealed an incidental hypermetabolic focal lesion in the right testicle—no other specific findings in the remaining parts of the body nor definitive FDG avid lymphadenopathy to suggest PTLD. Testicular US was requested and showed a well-defined right-sided heterogeneous hypoechoic intratesticular focal mass at the upper pole of the right testis with significant internal vascularity on the color Doppler imaging. The patient underwent a right radical orchidectomy, and the tumor was pathologically confirmed as an LCT. Conclusion In our case, 18F-FDG-PET/CT has been helpful in incidentally detecting this rare testicular tumor in a patient with suspected PTLD.

Download Full-text

FDG PET-CT in breast cancer: A single institution experience from India.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e11027 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e11027-e11027

Author(s):

Nalini K Rao ◽

Basavalinga S Ajaikumar ◽

Kumar G Kallur ◽

P S Sridhar ◽

Bhattacharjee Somorat ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Fdg Pet ◽

Treatment Plan ◽

Whole Body ◽

Breast Cancer Patients ◽

Term Survival ◽

New Findings ◽

Pet Ct ◽

Fdg Pet Ct

e11027 Background: Whole body FDG PET CT is a useful tool in diagnosis, staging and prognosis; and its timely use is critical for early intervention and achieving long term survival in patients with early and advanced breast cancer. Methods: In this observational retrospective study, we report FDG PET CT findings of all breast cancer patients enrolled in our hospital based cancer registry between the years 2008 to 2011. Results: One thousand and fifty three women underwent a total of 1638 scans. Two hundred and forty five scans (14.96%) were done for staging /restaging/diagnosis, 1208 (73.75%) were for response evaluation to chemotherapy and 185 (11.29%) were for surveillance. The median age at diagnosis was 53 years. We identified a possible synchronous breast primary in 28 (2.66%) women and a probable new or existing second non-breast primary in 21(1.99%) women. Internal nodal metastasis was identified in 76 (7.21%) women at diagnosis. There were 26 (2.47%) patients with multicentric tumors. There was an increased uptake in the thyroid gland in 49(2.99%) and in the adrenal in 41 (2.50%) women. There were other random ‘Incidental findings of concern’ in 7 (0.37%) of women, diagnosed either on the CT or PET-CT component. Findings on PET-CT, including- upstaging of the breast primary and unexpected new findings, unrelated to the breast primary, changed the treatment plan in approximately 7% -10% of the patients. We did find that PET-CT did not impact early tumors; however, it did contribute in, 1) the assessment of internal mammary nodes, 2) prognostication based on tumor burden and, 3) aggressive management of oligometastases. Conclusions: Whole body FDG PET CT is a useful tool for staging and prognostication in breast cancer patients. However, the timing of such scans for surveillance needs to be defined for early detection of progression to have an impact on survival.

Download Full-text

FDG PET/CT imaging for prognosis of metastatic non-iodine avid differentiated thyroid cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e17555 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e17555-e17555 ◽

Cited By ~ 1

Author(s):

Poorni Manohar ◽

David Brandel ◽

Emily Light Bellile ◽

Francis P. Worden ◽

Anca M Avram

Keyword(s):

Thyroid Cancer ◽

Fdg Pet ◽

Differentiated Thyroid Cancer ◽

Ct Imaging ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Dynamic and Parametric Whole-Body FDG PET/CT Imaging in Oncology: Is it Feasible in Routine Clinical Practice?

Clinical Radiology & Imaging Journal ◽

10.23880/crij-16000185 ◽

2021 ◽

Vol 5 (1) ◽

Author(s):

Sundaraiya S

Keyword(s):

Clinical Practice ◽

Fdg Pet ◽

Ct Imaging ◽

Routine Clinical Practice ◽

Whole Body ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Incremental diagnostic value of [18F]tetrafluoroborate PET-CT compared to [131I]iodine scintigraphy in recurrent differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s00259-020-04727-9 ◽

2020 ◽

Vol 47 (11) ◽

pp. 2639-2646 ◽

Cited By ~ 2

Author(s):

Matthias Dittmann ◽

José Manuel Gonzalez Carvalho ◽

Kambiz Rahbar ◽

Michael Schäfers ◽

Michael Claesener ◽

...

Keyword(s):

Thyroid Cancer ◽

Fdg Pet ◽

Differentiated Thyroid Cancer ◽

Imaging Techniques ◽

Diagnostic Value ◽

Whole Body ◽

Sodium Iodide Symporter ◽

Cervical Lymph Nodes ◽

Pet Ct ◽

Fdg Pet Ct

Abstract Introduction Efficient therapy of recurrent differentiated thyroid cancer (DTC) is dependent on precise molecular imaging techniques targeting the human sodium iodide symporter (hNIS), which is a marker both of thyroid and DTC cells. Various iodine isotopes have been utilized for detecting DTC; however, these come with unfavorable radiation exposure and image quality ([131I]iodine) or limited availability ([124I]iodine). In contrast, [18F]tetrafluoroborate (TFB) is a novel radiolabeled PET substrate of hNIS, results in PET images with high-quality and low radiation doses, and should therefore be suited for imaging of DTC. The aim of the present study was to compare the diagnostic performance of [18F]TFB-PET to the clinical reference standard [131I]iodine scintigraphy in patients with recurrent DTC. Methods Twenty-five patients with recurrent DTC were included in this retrospective analysis. All patients underwent [18F]TFB-PET combined with either CT or MRI due to newly discovered elevated TG levels, antiTG levels, sonographically suspicious cervical lymph nodes, or combinations of these findings. Correlative [131I]iodine whole-body scintigraphy (dxWBS) including SPECT-CT was present for all patients; correlative [18F]FDG-PET-CT was present for 21 patients. Histological verification of [18F]TFB positive findings was available in 4 patients. Results [18F]TFB-PET detected local recurrence or metastases of DTC in significantly more patients than conventional [131I]iodine dxWBS and SPECT-CT (13/25 = 52% vs. 3/25 = 12%, p = 0.002). The diagnosis of 6 patients with cervical lymph node metastases that showed mildly increased FDG metabolism but negative [131I]iodine scintigraphy was changed: [18F]TFB-PET revealed hNIS expression in the metastases, which were therefore reclassified as only partly de-differentiated (histological confirmation present in two patients). Highest sensitivity for detecting recurrent DTC had the combination of [18F]TFB-PET-CT/MRI with [18F]FDG-PET-CT (64%). Conclusion In the present cohort, [18F]TFB-PET shows higher sensitivity and accuracy than [131I]iodine WBS and SPECT-CT in detecting recurrent DTC. The combination of [18F]TFB-PET with [18F]FDG-PET-CT seems a reasonable strategy to characterize DTC tumor manifestations with respect to their differentiation and thereby also individually plan and monitor treatment. Future prospective studies evaluating the potential of [18F]TFB-PET in recurrent DTC are warranted.

Download Full-text

Variation of system performance, quality control standards and adherence to international FDG-PET/CT imaging guidelines

Nuklearmedizin ◽

10.3413/nukmed-0665-14-05 ◽

2014 ◽

Vol 53 (06) ◽

pp. 242-248 ◽

Cited By ~ 23

Author(s):

H. Bergmann ◽

B. Geist ◽

M. Schaffarich ◽

A. Hirtl ◽

M. Hacker ◽

...

Keyword(s):

Quality Control ◽

Fdg Pet ◽

Ct Imaging ◽

Public Hospitals ◽

Whole Body ◽

Whole Body Imaging ◽

Glucose Levels ◽

Pet Ct ◽

Ct System ◽

Fdg Pet Ct

Summary Aim: To gather information on clinical operations, quality control (QC) standards and adoption of guidelines for FDG-PET/CT imaging in Austrian PET/CT centres. Methods: A written survey composed of 68 questions related to A) PET/CT centre and installation, B) standard protocol parameters for FDG-PET/CT imaging of oncology patients, and C) standard QC procedures was conducted between November and December 2013 among all Austrian PET/CT centres. In addition, a NEMA-NU2 2012 image quality phantom test was performed using standard whole-body imaging settings on all PET/CT systems with a lesion-to- background ratio of 4. Recovery coefficients (RC) were calculated for each lesion and PET/ CT system. Resu lts: A) 13 PET/CT systems were installed in 12 nuclear medicine departments at public hospitals. B) Average fasting prior to FDG-PET/CT was 7.6 (4-12) h. All sites measured blood glucose levels while using different cut-off levels (64%: 150 mg/dl). Weight- based activity injection was performed at 83% sites with a mean FDG activity of 4.1 MBq/kg. Average FDG uptake time was 55 (45-75) min. All sites employed CT contrast agents (variation from 1 %-95% of the patients). All sites reported SUV-max. C) Frequency of QC tests varied significantly and QC phantom measurements revealed significant differences in RCs. Conclusion: Significant variations in FDG-PET/CT protocol parameters among all Austrian PET/CT users were observed. subsequently, efforts need to be put in place to further standardize imaging protocols. At a minimum clinical PET/CT operations should ensure compliance with existing guidelines. Further, standardized QC procedures must be followed to improve quantitative accuracy across PET/CT centres.

Download Full-text